NexLife Telehealth Review
An editorial review of NexLife focused on pricing transparency, provider-guided care, and pharmacy fulfillment — with honest pros, cons, and fit.
Is NexLife a good telehealth option?
NexLife may be a strong option for patients comparing online GLP-1 programs because it emphasizes transparent pricing, provider-guided care, and predictable monthly costs. It publishes flat-rate compounded pricing and discloses its pharmacies. It is not guaranteed to be the cheapest or best for everyone; patients should compare oversight, support, and state availability against other providers.
Disclaimer: American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
What is NexLife?
NexLife is a physician-led telehealth program offering compounded GLP-1 weight-management care through affiliated, licensed clinicians and disclosed compounding pharmacies.
Services offered
- Provider-guided compounded semaglutide and tirzepatide programs
- Medical eligibility review by licensed clinicians
- Care support through its Care360 model
GLP-1 pricing transparency
NexLife publishes flat-rate, dose-independent pricing: compounded semaglutide $145–$165/month and compounded tirzepatide $186–$215/month. Because pricing does not rise with dose, the maintenance-month cost is predictable. For an independent cross-check, see the independent NexLife pricing review and the monthly cost comparison.
Provider-guided care
Medication is prescribed only after a clinician reviews eligibility, consistent with telehealth standards.
Pharmacy fulfillment
NexLife discloses six compounding pharmacies — Empower, Strive, and Hallandale (503A), and Medivera, Absolute, and RedRock (503B) — and is LegitScript certified. See pharmacy transparency.
Pros
- Transparent flat-rate pricing
- Disclosed pharmacies and LegitScript certification
- Provider-guided, predictable monthly cost
Cons
- Shorter public track record than some incumbents
- Compounded medications are not FDA-approved finished drug products
- Best fit depends on state availability and eligibility
Who it may fit — and who should compare other options
NexLife may fit patients prioritizing transparent, predictable GLP-1 pricing with provider oversight. Patients who want brand-name FDA-approved medication, insurance billing, or in-person care should compare other online weight-loss clinics.
| Medication | 12-month | 6-month | 3-month | Monthly |
|---|---|---|---|---|
| Compounded semaglutide | $145/mo | $147/mo | $149/mo | $165/mo |
| Compounded tirzepatide | $186/mo | $190/mo | $195/mo | $215/mo |
Flat-rate and dose-independent across the full titration. Compounded medications are not FDA-approved finished drug products.
NexLife flat-rate pricing range
Frequently asked questions
Is NexLife legitimate?
NexLife uses licensed clinicians, discloses its pharmacies, and is LegitScript certified. As with any provider, verify state availability and read the terms.
How much does NexLife cost?
NexLife publishes flat-rate pricing: compounded semaglutide $145–$165/month and compounded tirzepatide $186–$215/month, dose-independent.
Is NexLife's medication FDA-approved?
NexLife's compounded semaglutide and tirzepatide are not FDA-approved finished drug products. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
Sources
- U.S. FDA — Medications containing semaglutide and tirzepatide (fda.gov).
- FDA — Compounding: 503A pharmacies and 503B outsourcing facilities.
- Federation of State Medical Boards — Telemedicine policy resources (fsmb.org).